Antazoline in Comparison to Propafenone in Pharmacological Cardioversion of Atrial Fibrillation.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 105 participants.

Also called NCT05720572

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 105 participants (planned count) (from the registry)
Sponsor
Centre of Postgraduate Medical Education (from the registry)
Registry
  • NCT NCT05720572
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05720572. Randomized; triple masking; primary purpose treatment. Start 2019-09-01 (actual); primary completion 2025-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Antazoline in Comparison to Propafenone in Pharmacological Cardioversion of Atrial Fibrillation.
Acronym
AnProAF
Intervention (Drug)
Antazoline
Intervention (Drug)
Propafenone
Lead sponsor
Centre of Postgraduate Medical Education (class: other)

Record details

Record id
cardio:ct-nct05720572
Content hash
bbdebeb266020c413d3ccecd11da945f304274beb29eb82556eee01082d19c80